Drugs / CAT-101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07396090 | Jan → Oct 2026 expected | — | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAT-101 | “mKRAS antigen-loaded engineered dendritic cells (eDCs, designated as CAT-101)” NCT07396090 ↗ |
| Modality | Cell therapy | “mKRAS antigen-loaded engineered dendritic cells” NCT07396090 ↗ |
| Route | Intravenous | “intravenous injection” NCT07396090 ↗ |
| Target | KRAS | “KRAS-Specific Vaccine” NCT07396090 ↗ |